Abstract # 2201 Baseline Albumin/Bilirubin Ratio (ABR) as a Predictor of Yttrium-90 Microsphere (TheraSphere) Treatment Outcome

Presenter: Kelly, Douglas

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos

About the Presenter:
Dr. Doug Kelly is a radiation oncologist at Cancer Treatment Centers of America in Tulsa, OK.

D. A. Kelly, F. Brunk, A. Sen, J. P. Flynn, M. West, A. Movahed, F. Pascual, Cancer Treatment Centers of America, Tulsa, OK

Author Disclosure:
 D.A. Kelly, None; F. Brunk, None; A. Sen, None; J.P. Flynn, None; M. West, None; A. Movahed, None; F. Pascual, None.

Click on images to enlarge (a new pop-up window will open)

Entire Poster:

E-mail a friend about this abstract:
Enter email address: